The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) for Philadelphia chromosome positive (Ph þ ) acute lymphoblastic leukemia (ALL) is uncertain. We analyzed 197 adults with Ph þ ALL in first complete remission; 67 patients receiving RIC were matched with 130 receiving myeloablative conditioning (MAC) for age, donor type and HCT year. Over 75% received pre-HCT tyrosine kinase inhibitors (TKIs), mostly imatinib; 39% (RIC) and 49% (MAC) were minimal residual disease (MRD) neg pre-HCT. At a median 4.5 years follow-up, 1-year transplant-related mortality (TRM) was lower in RIC (13%) than MAC (36%; P ¼ 0.001) while the 3-year relapse rate was 49% in RIC and 28% in MAC (P ¼ 0.058). Overall survival (OS) was similar (RIC 39% (95% confidence interval (CI) 27-52) vs 35% (95% CI 27-44); P ¼ 0.62). Patients MRD pos pre-HCT had higher risk of relapse with RIC vs MAC (hazard ratio (HR) 1.97; P ¼ 0.026). However, patients receiving pre-HCT TKI in combination with MRD negativity pre-RIC HCT had superior OS (55%) compared with a similar MRD population after MAC (33%; P ¼ 0.0042). In multivariate analysis, RIC lowered TRM (HR 0.6; P ¼ 0.057), but absence of pre-HCT TKI (HR 1.88; P ¼ 0.018), RIC (HR 1.891; P ¼ 0.054) and pre-HCT MRD pos (HR 1.6; P ¼ 0.070) increased relapse risk. RIC is a valid alternative strategy for Ph þ ALL patients ineligible for MAC and MRD neg status is preferred pre-HCT.
INTRODUCTION
Philadelphia chromosome positive (Ph þ ) acute lymphoblastic leukemia (ALL) is the largest genetically defined subset, affecting about 25% of adults with ALL; particularly those older than 40 years. 1 The poor survival of Ph þ ALL patients treated with chemotherapy alone (10%) has been substantially improved through the use of allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR1) and more recently, by combining tyrosine kinase inhibitors (TKIs) with induction and post-remission chemotherapy. [2] [3] [4] [5] The anti-leukemia effect of HCT is through chemotherapy and/or radiation used in the preparative regimen and through an immune-mediated graft-vs-leukemia effect. [5] [6] [7] [8] Although widespread use of TKIs has changed the landscape of Ph þ ALL management, myeloablative conditioning (MAC) followed by the allogeneic HCT remains the only established curative therapy. Incorporating TKIs into induction chemotherapy has not increased toxicity, but has substantially improved remission rates and facilitated more allotransplants in CR1. 9, 10 Furthermore, several prospective clinical trials testing an imatinib-containing strategy consolidated with a MAC alloHCT showed overall survival (OS) ranging from 40 to 65%, which is markedly better than historical pre-imatinib controls (OS 20-40%). [2] [3] [4] [11] [12] [13] However, many patients are not eligible for a conventional MAC regimen because of their age and comorbidities. High transplant-related mortality (TRM) remains a serious problem in older adults, which negates the survival benefit gained through protection from relapse by full intensity conditioning and graft-vs-leukemia.
14 For these reasons, reduced intensity conditioning (RIC) HCT was developed to allow engraftment and harness the graft-vsleukemia effect while potentially limiting TRM in patients unfit for full intensity conditioning regimens.
To date, there are no large-scale data on the efficacy of RIC HCT for Ph þ ALL. Most single institution studies lack detail on ALL subset-specific outcomes. [15] [16] [17] [18] [19] The utility of RIC HCT for ALL was recently demonstrated in a CIBMTR study for Ph-negative ALL, in which similar rates of TRM, relapse and survival (43% vs 38%) between RIC and MAC were observed. 20 A European Bone Marrow Transplant Registry study, which included 41 Ph þ patients in a RIC cohort, showed comparable OS between RIC and MAC groups. 21 However, the limited details on minimal residual disease (MRD) and TKI use make the interpretation of these studies problematic. Indeed, the definition of remission in Ph þ ALL now routinely includes tools to assess the depth of remission by cytogenetic testing of interphase cells for t(9;22) (fluorescent in situ hybridization (FISH)) and PCR for detection of chimeric mRNA arising from BCR-ABL1 genomic recombination. FISH assay allows the sensitivity between 0.5 and 3%, whereas real-time PCR and nested PCR allow quantification of MRD to the 1:10 5 -10 6 cell level. 22 Both assays are widely used to monitor response and guide therapeutic choices. 17, [23] [24] [25] [26] Several studies in adult Ph þ ALL have confirmed that patients with MRD persistence 6-10 weeks after initiating induction therapy have a higher risk of relapse, yet early myeloablative allogeneic donor HCT can sometimes overcome MRD pos and cure a subset of patients. 25, 27 The sensitivity of Ph þ ALL to non-ablative chemotherapy/radiation and to graft-vs-leukemia in the setting of RIC HCT is not well established. To address these issues, we performed a multicenter registry-based analysis investigating the outcomes of RIC allogeneic HCT for Ph þ ALL. Using a matched pair design, we examined a cohort of patients with Ph þ ALL in CR1 and compared survival after RIC or MAC allogeneic transplantation, as well as the effect of TKI use and pre-HCT MRD status on transplant outcomes.
PATIENTS AND METHODS

Data source
The 26 Umbilical cord blood donors, mismatched related donor and ex vivo T-cell-depleted grafts were excluded. Preparative regimens were classified either as RIC or MAC according to published consensus definitions. 28 The CIBMTR definition of RIC included regimens containing melphalanp150 mg/m 2 (n ¼ 24), busulfanp9 mg/kg orally (n ¼ 20), total body irradiation o5 Gy (n ¼ 11), fludarabine-total body irradiation combinations (n ¼ 17) or fludarabine-based conditioning (n ¼ 5). The MAC preparative regimen consisted mostly of total body irradiation (n ¼ 108) or busulfan combinations (n ¼ 22). RIC patients were matched with MAC patients on three factors: age (within 15 years), type of donor (related vs unrelated donor) and year of transplant (within 5 years). A supplemental data form was developed to collect: (1) presence of pre-HCT MRD in bone marrow immediately before conditioning tested by FISH and/or by PCR for the BCR-ABL (yes/no); and (2) use of TKIs (imatinib, nilotinib or dasatinib) delivered at any time before transplantation and the duration of TKI therapy. We also collected data on post-transplant TKI administration, defined as maintenance therapy (excluding treatment given for cytogenetic or morphologic relapse), start date and duration of maintenance. Retrospectively, collecting the MRD data from many centers reflect the real world clinical practice where both BCR/ABL transcript levels and/or FISH analysis are often obtained in patients with morphologic CR. The stringency of MRD determination using each center's testing sensitivity with these approaches could not be addressed in this multicenter analysis. Data on post-transplant MRD monitoring were not collected. The final study population excluded MAC patients not selected by the matching strategy (n ¼ 241) and those without supplemental data (n ¼ 32). The return rate on supplemental forms requested on 243 cases from 76 centers was 86.4%. Each participating center enrolled an average 2.5 cases (range 1-15 cases).
Definitions, study end points and statistical analysis
The primary outcomes were OS after HCT defined as the time from transplantation to death, disease-free survival (DFS), relapse incidence and TRM. Surviving patients were censored at the time of last contact. Secondary end points were grades II-IV acute graft-vs-host disease (aGVHD) and chronic GVHD (cGVHD). Probability of DFS and OS were calculated using the Kaplan-Meier estimator, with the variance estimated by Greenwood's formula. Values for other end points were calculated using cumulative incidence curves to accommodate competing risks. 29 We defined the MRD status as MRD pos (Ph þ by FISH positive and/or positive BCR-ABL by PCR) and pre-HCT MRD neg (Ph þ FISH negative and/or negative BCR-ABL by PCR). Use of TKI was defined as pre-HCT TKI (including 41 patients who received TKI both pre and post-HCT) or no TKI at any time-point. The risk factors considered in the stepwise model building procedures were conditioning regimen intensity (main effect), age, gender, pre-HCT MRD positivity, TKI use pre-HCT (yes/no), year of HCT and cGVHD as a time-dependent covariate. The potential interactions between the main effect (conditioning regimen) and MRD, TKI and other significant variables were examined.
RESULTS
Patients characteristics
Data on 197 eligible patients from 14 different countries and 76 reporting centers were analyzed. Sixty-seven RIC patients were matched for analysis 1:2 (n ¼ 63) or 1:1 (n ¼ 4) to 130 MAC patients for age, donor type and year of transplant (Table 1) . Median age in the RIC and MAC groups was 54 and 50 years, respectively, (P ¼ 0.02). White blood cell count at diagnosis and performance status at time of transplant were similar for both groups. Previous fungal infections were more common in the RIC group (12% vs 3%; P ¼ 0.006). RIC recipients had a longer median time from diagnosis to HCT (6 months (interquartile range 4.8-7.4 months) vs MAC: 5 months (interquartile range 4.2-6.8 months; P ¼ 0.03)), but the time from diagnosis to CR1 was similar (median 42 days (interquartile range 34-82 days) and 52 days (interquartile range 31-111 days; P ¼ 0.76)) in RIC and MAC groups. Over half of patients in both groups had co-existent morbidities or organ impairment (61% in RIC and 58% in MAC; P ¼ 0.12). Significantly more RIC patients had a pre-HCT comorbidity index of X1 as compared with MAC patients (19% vs 8%; P ¼ 0.03). 30 Both RIC and MAC groups used peripheral blood grafts more often than bone marrow grafts and had similar use of related donors (39 and Ph þ ALL RIC transplant outcomes V Bachanova et al 38%) and matched unrelated donor (42% for both). GVHD prophylaxis was similar in both groups with cyclosporine or tacrolimus-containing regimens used most often. RIC patients more often received anti-thymocyte globulin or campath (37% vs 17%; P ¼ 0.03). The remaining variables of donor/recipient sex, donor/recipient CMV status and year of transplant were balanced. Median follow-up of survivors was 49 months (range 3-108 months) for the RIC group and 61 months (range 3-119 months) for the MAC group.
MRD assessment and use of TKI inhibitors All patients were in CR1 by morphologic criteria. Reflecting the clinical practice, more patients had pre-HCT bone marrow MRD pos pre-HCT. The median time to TKI administration after RIC HCT was 1.5 months (interquartile range: 0.9-3.5 months), about 1 month earlier than MAC HCT (2.9 months (interquartile range 1.7-5.5 months); P ¼ 0.095). Forty-one patients (20%) were not treated with TKI agents at any time.
DFS and OS At 3 years, DFS and OS for the RIC group were 26% (95% confidence interval (CI) 16-37%) and 39% (95% CI 27-52%), respectively, and were similar to the MAC group (28% (95% CI 20-36%) and 35% (95% CI 27-44%); Table 2 ). In univariate analysis, pre-HCT MRD status did not impact survival in either group (Figure 1b) . Sex, peripheral white blood cell at diagnosis and year of HCT did not significantly affect OS in univariate analysis (male gender hazard ratio (HR): 1.17 (95% CI 0.8-1.6); white blood cell4100 Â 10 9 /l: HR 0.6 (95% CI 0.32-1.1), 2005-2009 HR: 1.05 (95% CI 0.7-1.5)). Within the RIC group, both pre-HCT TKI and concomitant MRD neg status yielded the best 3-year OS (55% (95% CI 31-77%)), which compared favorably with the same patients (MRD neg with pre-HCT TKI) in the MAC group (33% (95% CI 20-48%); P ¼ 0.0042).
In multivariate analysis, RIC did not significantly influence OS (HR 0.87; P ¼ 0.48) or DFS (HR 1.1; P ¼ 0.58; Table 3 ). Age above 40 years was associated with significantly worse survival (HR 1.92), but pre-HCT MRD status, pre-HCT TKI use and the development of cGVHD did not significantly alter OS or DFS (Table 3) .
TRM and causes of death The cumulative incidence of TRM at day 100 was 10% in the RIC group (95% CI 4-19%) and 19% in the MAC group (95% CI 13-26%; P ¼ 0.11), while at 1 year it was almost threefold lower in the RIC than in the MAC group (13% vs 36%; Po0.001; Figure 1c) . In adjusted multivariate analysis, RIC was associated with reduced TRM risk (HR 0.60; P ¼ 0.059). Age over 40 years increased the risk of TRM 3-fold and cGVHD increased TRM risk 1.7-fold ( Table 3) . The most common cause of death in the RIC group was relapse (n ¼ 13) followed by infection (n ¼ 10), organ failure (n ¼ 6) and GVHD (n ¼ 4). MAC patients died most often of GVHD (n ¼ 22), relapse (n ¼ 16) and infection (n ¼ 12). Death attributed to GVHD was more common after MAC compared with RIC HCT (P ¼ 0.1).
Relapse
The incidence of relapse at 3 years was higher in the RIC group (49%) than in the MAC group (28%) although not statistically significant (P ¼ 0.058; Table 2 ). Given that pre-HCT MRD and use of TKI could potentially modify relapse risk, we examined relapse risks in specified subgroups. The cumulative incidence of relapse at 3 years in pre-HCT MRD pos patients was significantly higher after RIC 61% (95% CI 45-76%) than MAC HCT (35% (95% CI 24-48%); HR 1.97 (1.09-3.57; P ¼ 0.026); Figure 1a ). However, pre-HCT MRD neg patients had similar relapse risks after RIC or MAC transplants (31% (95% 15-50%) vs 21% (11-32%); P ¼ 0.15). Low relapse rate was also observed in subset of patients who were pre-HCT BCR/ABL neg (RIC 16% (95% CI 7-28); MAC 25% (9-46%); P ¼ 0.36).
In the RIC group, pre-HCT TKI therapy was associated with twofold reduction in 3-year relapse incidence (38% (95% CI 25-52%)) as compared with no pre-HCT TKI (81% (95% CI 59-96%); P ¼ 0.0039). In contrast, in the MAC group no protection from relapse by pre-HCT TKI was observed (26% (95% CI 18-35%) vs 33% (95% CI 17-52%); P ¼ 0.51). Remarkably, low rates of relapse were observed in patients who received pre-HCT TKI who were also pre-HCT MRD neg (RIC 17% (95% CI 4-37%) and MAC HCT 20% (95% CI 10-33%)). For these patients, the conditioning regimen intensity did not influence relapse risk. The 3-year relapse was not impacted by TKI post-transplant maintenance neither in the RIC cohort (TKI maintenance 59% vs no TKI 45%; P ¼ 0.63) nor in the MAC cohort (TKI maintenance 27% vs no TKI 28%; P ¼ 0.26), although only 43 patients were treated with TKI post-transplant. 
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The median time from HCT to relapse was similar at 11 months in the RIC group (range 1-103 months) and 9 months in the MAC group (range 1-119 months; P ¼ 0.60).
In adjusted multivariate analysis, RIC was associated with increased risk of relapse (HR 1.84; P ¼ 0.011). Although age (440 years) and cGVHD did not influence relapse risk, no TKI use pre-HCT (HR 1.88; P ¼ 0.018) was independently associated with an increased risk of relapse. Pre-HCT MRD pos (HR 1.6 (95% CI 0.96-2.67)) was associated with increased relapse risk, but did not reach statistical significance (Table 3) .
Donor lymphocyte infusions and second transplant Fourteen patients received donor lymphocyte infusion (DLI) posttransplant (RIC 3; MAC 11). Six DLI infusions were administered for Abbreviations: CI, confidence interval; GVHD, graft vs host disease; HCT, hematopoietic cell transplantation; HR, hazard ratio; MRD, minimal residual disease; TKI, tyrosine kinase inhibitor. *Includes both FISH and BCR/ABL PCR.
Ph þ ALL RIC transplant outcomes V Bachanova et al relapsed ALL and all were in the MAC cohort. None of the six patients survive. Three of eight patients who received DLI for nonrelapse indications are alive (two in RIC and one in MAC cohort). Seventeen other patients underwent second HCT for relapsed ALL (RIC cohort 6 and MAC cohort 11) and 3 (17%) survive (2 in RIC and 1 in the initial MAC cohort) after their second HCT.
Graft-vs-host disease The cumulative incidence of grades II-IV aGVHD at day 100 was lower in the RIC (30% (95% CI 20-42%)) than the MAC group (47% (95% CI 39-56%); P ¼ 0.014). The incidence of cGVHD at 1 year was similar (RIC 46% (95% CI 34-58%) vs MAC 41% (95% CI 32-50%); P ¼ 0.38). Given the recent use of TKIs for treatment of cGVHD, we analyzed the relationship between GVHD and TKI administration after HCT. The median time from HCT to aGVHD diagnosis was 0.9 month (range 0.2-2.7 months), while the median time to start TKI therapy post-transplant was later: 2.3 months (range 0.5-36 months). More importantly, the time from HCT to cGVHD onset was similar in the subgroup treated with TKI (4.4 months) vs no TKI therapy (5.8 months). In addition, TKI administration after HCT did not reduce the incidence of cGVHD as the proportion of patients with cGVHD was similar with or without post-HCT TKI (63% vs 45%; P ¼ 0.87). In multivariate analysis, pre-HCT MRD and TKI use did not impact risks of aGVHD or cGVHD. After adjusting for age, MRD and TKI use, the risk of aGVHD was significantly lower in the RIC group (HR 0.54; P ¼ 0.014; Table 3 ), whereas the risk of cGVHD was not altered by conditioning regimen intensity.
DISCUSSION
To examine the role of conditioning regimen intensity, MRD and TKI influences on HCT for ALL, we conducted a multicenter retrospective matched-pair analysis of 197 Ph þ ALL patients undergoing RIC and MAC allogeneic HCT in CR1. The strength and clinical applicability of this study is enhanced by the incorporation of data on pre-HCT MRD status and administration of TKI pre-HCT-two critical outcome-modifying variables. In addition, given the matched pair study design, the median age of 52 years closely reflects the HCT population with Ph þ ALL. The main finding is that DFS and OS in Ph þ ALL were similar after RIC and MAC allogeneic HCT, confirming the curative potential of allogeneic HCT after a reduced intensity preparative regimen. The relatively mature follow-up of 4 years suggests that long-term survival can be achieved for about 40% of older patients with Ph þ ALL after RIC HCT. Hence, RIC extends the benefit of allotransplant to patients above age 50 and to those who are otherwise ineligible for conventional MAC HCT. Although there is still considerable room for improvement, these results are encouraging given the disappointing long-term outcomes observed without HCT. In some studies, patients ineligible for HCT have been treated with TKI-based maintenance therapy. 3, 4, 31, 32 Although early results with short follow-up were promising, late relapses still occurred after a median duration of remission of 20-25 months and this approach currently cannot be considered curative. Most relapses were associated with a highly resistant phenotype and BCR-ABL gene mutations including T315I. 33, 34 As a result, the value of RIC HCT compared with chemotherapy plus TKI for older patients with Ph þ ALL remains a key issue for future prospective trials.
RIC HCT conferred the most significant benefit to the patients who were MRD neg before allograft and had received TKI pre-HCT. Indeed, the twofold increase in relapse in patients with pre-HCT MRD pos evident only in the RIC group suggests that a less intense regimen may not overcome the presence of residual detectable leukemia and that caution is needed when RIC is considered for MRD pos patients. Notably, higher use of ATG in RIC group may contribute to higher relapse risk. 35 Nevertheless, the favorable outcomes in MRD neg patients suggest that achieving a MRDnegative state before HCT is vitally important and highlight the need to use effective therapy or perhaps second-generation/thirdgeneration TKI pre-HCT for those MRD pos patients in whom RIC is planned. 38 In our study, both pre-HCT TKI and MRD neg status in RIC patients best protected patients from relapse (only 17% relapsed) and were associated with superior OS of 55%. Use of TKI pre-HCT could lead to deeper MRD negativity; however, off-target immunomodulatory antileukemia effects of TKI have been also reported. Interestingly, recent clinical studies suggested development of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph þ ALL during long-term imatinib treatment. 36 In addition to TKI, other targeted therapeutic interventions such as blinatumomab and cellular infusions could also be of benefit if used before RIC HCT or peritransplant. [36] [37] [38] [39] [40] Importantly, we showed that reducing the intensity of the preparative regimen can substantially lower risks of aGVHD and TRM. This finding is particularly important because higher risks of TRM limit the utility of HCT, particularly for older individuals in whom Ph þ ALL is often diagnosed.
14 The observed low TRM (13% at 1 year) is striking, even acknowledging the inherent selection bias associated with RIC patients, who are usually at a greater risk of transplant-related toxicity.
As a result of the retrospective registry study design, we were not able to quantify the depth of MRD and its influence on survival. Both assays have limitations and while PCR is highly sensitive, false-negative results can be seen because of exquisite susceptibility of RNA to degradation. 22 Variations in transcript levels detectable by PCR complemented by assessment using FISH temper, the implications of these data and highlight the need for prospective validation using standardized BCR/ABL testing. Nevertheless, Ph þ ALL remains an important ALL subset for which RIC HCT is being tested and until prospective trial results become available, our analysis provides real life, clinically relevant insights on allograft approaches for patients with Ph þ ALL in morphologic remission. Current evidence suggests that MRD pos status after induction/consolidation chemotherapy predicts for an increased risk of relapse and worse survival. In a prospective study by Bassan et al. 41 on 236 patients, 48% remained MRD pos after induction/consolidation and 36 patients (66%) underwent HCT rescuing a proportion of MRD pos by MAC HCT. Our data also suggest that MAC allotransplantation can reduce the adverse relapse risk conferred by a pre-HCT MRD pos status. Other studies reported evidence that MRD pos patients treated with allogeneic HCT can have successful outcomes, [24] [25] [26] although post-transplant persistence of MRD pos most often predicts imminent relapse and poor DFS. A recent GRALL report showed improved OS after imatinib-based chemotherapy followed by MAC HCT (50%) compared with no allo-HCT (33%). Although MRD pos predicted higher risk of relapse, it did not influence OS. 4 The emerging future question of great importance is the value serial monitoring of BCR/ABL post-transplant and screening for BCR/ABL mutations. Impact of post-HCT TKI on relapse in this study has to be interpreted with caution because 70-80% of patients did not receive TKI post-HCT in maintenance. This might reflect the earlier era of study or poor tolerance of TKI posttransplant related to myelosuppression or other adverse effects as reported. 11, 42 A recent German prospective trial randomized Ph þ ALL patients after MAC HCT to receive either maintenance imatinib or pre-emptive therapy with imatinib for molecular relapse. They concluded that post-transplant imatinib was often delayed or interrupted, but no difference in survival was observed with either approach. The study reported excellent OS of 70% in both groups; however, only those patients who were alive at day 60 were included in the analysis. 42 Other strategies of post-HCT manipulations such as DLI and second transplant are often available. Although rarely used in our cohort, these efforts did not significantly alter the outcome.
Ph þ ALL RIC transplant outcomes V Bachanova et al Our results provide directly applicable clinical data for clinicians and supports prospective application of RIC for Ph þ ALL patients who are ineligible for MAC such as the current prospective UKALL 14 clinical trial, which offers RIC HCT to Ph þ ALL patients older than 40 years. Our results suggest that achieving MRD neg status may lead to low relapse and prolonged survival from either MAC or RIC HCT and that MRD status and fitness rather than a predefined age cutoff may better guide decisions about conditioning intensity before allogeneic HCT. The use of TKI post-transplant requires further study before it can be considered standard of care.
